Armata Pharmaceuticals, Inc. (ARMP) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.69 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 47.37%. A quarter ago, it was expected that this company would post a loss of $0.35 per share when it actually produced a loss of $0.23, delivering a surprise of 34.29%.Over the last four quarters, the company ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to _______________________ Commission file number: 001-37544 ARMATA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) (Addre ...

Exhibit 99.1 Armata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate Update LOS ANGELES, CA, May 14, 2025 - Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its first quarter ended March 31, 2025, and p ...

LOS ANGELES, May 14, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its first quarter ended March 31, 2025, and provided a corporate update.First Quarter 2025 and Recent Developments: Anticipating announce ...

Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today:Armata Pharmaceuticals, Inc. (ARMP) is a clinical-stage biotechnology company. The Zacks Consensus Estimate for its current year earnings has been 14.1% downward over the last 60 days.Columbia Sportswear Company (COLM) is a lifestyle apparel and accessories company. The Zacks Consensus Estimate for its current year earnings has been revised 8.3% downward over the last 60 days.Eagle Financial Services, Inc. (EFSI) is a bank holding com ...

Phase 1b/2a diSArm trial evaluated AP-SA02 as a potential treatment for complicated Staphylococcus aureus bacteremia Topline data anticipated in Q2 2025 to support potential future pivotal bacteremia efficacy trialLOS ANGELES, May 1, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat ...

Group 1: Century Communities (CCS) - Century Communities is a home building and construction company operating in major metropolitan markets in Colorado, Texas, and Nevada [1] - The Zacks Consensus Estimate for its current year earnings has been revised 20.5% downward over the last 60 days [1] Group 2: Armata Pharmaceuticals (ARMP) - Armata Pharmaceuticals is a biotechnology company focused on developing bacteriophage therapeutics for antibiotic-resistant infections using proprietary technology [2] - The Zacks Consensus Estimate for its current year earnings has been revised almost 14.1% downward over the last 60 days [2] Group 3: Cable One (CABO) - Cable One is a cable company providing internet, cable television, and telephone services primarily in the United States [3] - The Zacks Consensus Estimate for its current year earnings has been revised 8.5% downward over the last 60 days [3]

Core Insights - Armata Pharmaceuticals reported significant clinical milestones and financial results for Q4 and full-year 2024, focusing on its bacteriophage therapeutics for antibiotic-resistant infections [1] Clinical Developments - The company achieved encouraging topline results from its Phase 2 Tailwind study for inhaled AP-PA02 in non-cystic fibrosis bronchiectasis (NCFB) patients, demonstrating a statistically significant reduction in Pseudomonas aeruginosa (P.a.) colony forming units (CFUs) [3][4] - AP-PA02 was well-tolerated, with mild and self-limiting treatment-emergent adverse events, and showed effectiveness comparable to antibiotic combination therapy [4] - Enrollment was completed for the Phase 1b/2a diSArm study evaluating AP-SA02 for Staphylococcus aureus bacteremia, with topline results expected in the first half of 2025 [3][4] Financial Performance - Grant revenue for Q4 2024 was $1.2 million, down from $1.5 million in Q4 2023, reflecting MTEC's share of costs for the AP-SA02 program [6] - Research and development expenses increased to approximately $8.5 million in Q4 2024 from $7.9 million in Q4 2023, indicating continued investment in clinical programs [7] - General and administrative expenses rose slightly to approximately $3.3 million in Q4 2024 from $3.2 million in Q4 2023, primarily due to increased personnel costs [8] Operational Loss and Net Income - The company reported a loss from operations of approximately $10.5 million in Q4 2024, compared to a loss of approximately $9.6 million in Q4 2023 [9] - Net income for Q4 2024 was $2.6 million, or $0.07 per share, contrasting with a net loss of $19.8 million, or $(0.55) per share, in Q4 2023, largely due to non-cash gains from changes in fair value of convertible loans [10] Cash Position - As of December 31, 2024, Armata held approximately $14.8 million in cash and cash equivalents, down from $19.2 million a year earlier [11] - The company entered into a $10 million secured credit agreement with Innoviva, with an annual interest rate of 14% [12] Strategic Focus - Armata remains committed to developing phage therapy as an alternative to broad-spectrum antibiotics, aiming to address the global health crisis of antimicrobial resistance [5]

Core Insights - Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing high-purity pathogen-specific bacteriophage therapeutics to treat antibiotic-resistant and difficult-to-treat bacterial infections [1][2] - The company is advancing a broad pipeline of natural and synthetic phage candidates targeting pathogens such as Pseudomonas aeruginosa and Staphylococcus aureus [2] Company Overview - Armata Pharmaceuticals utilizes proprietary bacteriophage-based technology for its therapeutic developments [2] - The company has in-house phage-specific cGMP manufacturing capabilities to support full commercialization of its products [2] Upcoming Events - Dr. Deborah Birx, the CEO of Armata, will present at the 7th Annual Bacteriophage Therapy Summit on March 13, 2025, in Boston, MA [1]

Core Insights - Armata Pharmaceuticals announced positive topline results from its Phase 2 "Tailwind" trial for AP-PA02, a novel inhaled multi-phage therapeutic targeting chronic pulmonary Pseudomonas aeruginosa infections in non-cystic fibrosis bronchiectasis patients [1][5] Study Design and Results - The Tailwind study was a multicenter, randomized, double-blind, placebo-controlled trial assessing the safety, pharmacokinetics, and efficacy of inhaled AP-PA02, conducted in two parallel cohorts [2] - Cohort A received AP-PA02 as monotherapy, while Cohort B received it in combination with inhaled antipseudomonal antibiotics, with dosing every 12 hours for 10 days and follow-up for approximately four weeks [2] - A post-hoc intent-to-treat analysis showed a statistically significant reduction in P.a. CFUs at day 17 (P=0.05) and day 24 (P=0.015) for AP-PA02 compared to placebo, indicating its effectiveness [3] - Approximately one-third of subjects treated with phage monotherapy exhibited at least a 2-log CFU reduction in P.a., while no reduction was observed in placebo subjects [3] Safety Profile - Safety data indicated that inhaled AP-PA02 was well-tolerated, with treatment-emergent adverse events being mild and self-limiting, although one serious adverse event was reported [4] Company Overview - Armata Pharmaceuticals is focused on developing pathogen-specific bacteriophage therapeutics for antibiotic-resistant bacterial infections, with a pipeline that includes candidates for Pseudomonas aeruginosa and Staphylococcus aureus [6]